MetaVia (MTVA)
NASDAQ:MTVA
MTVA Stock Chart & Stats
$1.41
-$0.13(-5.60%)
At close: 4:00 PM EST
$1.41
-$0.13(-5.60%)
Day’s Range― - ―
52-Week Range$1.17 - $23.10
Previous CloseN/A
Volume36.62K
Average Volume (3M)3.42M
Market Cap
$7.18M
Enterprise Value-$6.96M
Total Cash (Recent Filing)$10.28M
Total Debt (Recent Filing)$210.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.01
Shares Outstanding5,090,936
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap-0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit497.43
Enterprise Value/Ebitda0.52
Forecast
1Y Price Target
$14.00Price Target Upside892.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Tolerability And DosingEarly clinical data showed rapid and meaningful weight reduction with manageable gastrointestinal side effects and no study-related discontinuations, and a Phase One extension will refine dose-escalation strategies to balance effectiveness and tolerability.
Liver And Metabolic BenefitsAnalyst notes an early liver imaging signal indicating reduced liver stiffness and signs of metabolic improvement, supporting exploration of the drug's potential as a complementary treatment for obesity-related liver disease.
Mechanism DifferentiationAnalyst highlights that the lead drug's dual-action mechanism suppresses appetite while increasing energy expenditure, offering a distinct therapeutic approach that could differentiate it from current weight-loss treatments.
Bears Say
Financial Position And Funding RiskAnalyst warns the company is operating with ongoing losses and limited cash, increasing reliance on additional financing and raising financial risk for investors.
Market Competition And Commercial DifferentiationAnalyst cautions that a crowded obesity treatment market with emerging oral competitors could pressure uptake and pricing, meaning the drug will need clear clinical differentiation or a credible combination strategy to avoid being viewed as a me-too product.
Share Dilution And Valuation PressureA recent public offering raised the number of shares outstanding, diluting per-share value and contributing to a lower analyst price target.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $1.17 and its highest was $23.10 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $7.18M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is May 19, 2026 which is in 35 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on Mar 26, 2026. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of -$1.82 by $2.83.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MetaVia have?
MetaVia has 5,090,936 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of $1.01 in its last earnings report, beating expectations of -$1.82. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MetaVia
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MTVA Stock 12 Month Forecast
Average Price Target
$14.00
▲(892.91% Upside)